Microba Revenue and Competitors

Brisbane City, Australia

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Microba's estimated annual revenue is currently $15.5M per year.(i)
  • Microba's estimated revenue per employee is $155,000

Employee Data

  • Microba has 100 Employees.(i)
  • Microba grew their employee count by 9% last year.

Microba's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Head Healthcare Operations & DevelopmentReveal Email/Phone
3
Head Bioinformatics OperationsReveal Email/Phone
4
Head Laboratory OperationsReveal Email/Phone
5
SVP - ServicesReveal Email/Phone
6
VP, North America Sales - Platform SolutionsReveal Email/Phone
7
Quality Assurance OfficerReveal Email/Phone
8
Chief Scientific OfficerReveal Email/Phone
9
Chief Marketing OfficerReveal Email/Phone
10
Chief Financial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M19-27%N/AN/A
#2
$50.8M184-8%N/AN/A
#3
$12.6M902%$277MN/A
Add Company

What Is Microba?

Microba, a microbial genomics company originating from technology developed at the University of Queensland, has quickly established, itself as a world leader in analysis of the gut microbiome. With a growing body of global research indicating that the gut microbiome plays a central role in health and disease, Microba has positioned itself to be a leading force in the development of new pathology services, therapeutics and diagnostics. The Microba Insightâ„¢ Sampling kit offers the public access to cutting edge technology to analyse their personal gut microbiome. Using one of the most advanced sequencing technologies, Microba empowers consumers to gain a deeper understanding of their personal microbiome including the bacteria, archaea, fungi, and protists at the species level. Individuals receive a detailed overview of the microorganisms inhabiting their gut and what they might be doing, which can provide insight into overall gut health. Personalised dietary suggestions to promote the growth of beneficial bacteria is also included. Microba Insightâ„¢ is the only test in Australia that provides consumers with the whole picture. While other services use 16S rRNA testing, which only sequences a small part of a single bacterial gene, Microba uses metagenomics, which sequences all the genes from the microorganisms in a sample. Microba's co-founders, Professors Phil Hugenholtz and Gene Tyson, are two of the world's leading experts in microbiome analysis. They have pioneered many of the analysis methods used and published some of the highest impacting papers in the field.

keywords:N/A

N/A

Total Funding

100

Number of Employees

$15.5M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Microba News

2022-04-06 - Microba Appoints Therapeutics Head

Microba Appoints Therapeutics Head. Appointment of Professor Trent Munro as Senior Vice President of Therapeutics. Professor Munro has over 25...

2022-04-06 - Australia's Microba completes successful IPO

Microba is a commercial-stage company delivering gut microbiome testing services globally and driving the discovery of novel therapeutics.

2022-03-30 - Microba Completes Successful IPO

Microba is a commercial-stage company delivering gut microbiome testing services globally and driving the discovery of novel therapeutics. The...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$25.8M102-2%N/A
#2
$22.3M109-8%N/A
#3
$30.6M12526%N/A
#4
$37.3M1389%N/A
#5
$49.4M198466%N/A